Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KT 253

Next Previous
Drug Profile

KT 253

Alternative Names: KT-253

Latest Information Update: 28 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymera Therapeutics
  • Class Amides; Antineoplastics; Benzimidazoles; Chlorinated hydrocarbons; Chlorobenzenes; Cyclohexanes; Fluorobenzenes; Ketones; Piperazines; Piperidines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-mdm2 degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Merkel cell carcinoma
  • No development reported Acute myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 28 Apr 2026 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Apr 2026 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top